Mark E. Morrison

976 total citations · 1 hit paper
6 papers, 750 citations indexed

About

Mark E. Morrison is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Mark E. Morrison has authored 6 papers receiving a total of 750 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Organic Chemistry. Recurrent topics in Mark E. Morrison's work include melanin and skin pigmentation (2 papers), Neuroendocrine Tumor Research Advances (2 papers) and Peptidase Inhibition and Analysis (2 papers). Mark E. Morrison is often cited by papers focused on melanin and skin pigmentation (2 papers), Neuroendocrine Tumor Research Advances (2 papers) and Peptidase Inhibition and Analysis (2 papers). Mark E. Morrison collaborates with scholars based in United States. Mark E. Morrison's co-authors include Hariharan Subramanian, Lawrence H. Einhorn, Alan Sandler, Rafat Ansari, Troy H. Guthrie, Benjamin Wang, Nasser H. Hanna, Corey J. Langer, Thaddeus Beck and Paul A. Bunn and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Mark E. Morrison

6 papers receiving 724 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

2006 500 citations Nasser H. Hanna, Paul A. Bunn et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark E. Morrison United States	6	647	429	338	142	75	6	750
Patrick Fagan United States	11	70 0.1×	77 0.2×	334 1.0×	130 0.9×	20 0.3×	16	606
Taijie Jin China	9	79 0.1×	108 0.3×	455 1.3×	50 0.4×	19 0.3×	9	615
Monika Lamparska‐Przybysz Poland	10	109 0.2×	72 0.2×	299 0.9×	52 0.4×	8 0.1×	17	443
Eun Ryoung Jang United States	16	231 0.4×	70 0.2×	506 1.5×	29 0.2×	12 0.2×	24	657
Isabel Soto‐Cruz Mexico	15	208 0.3×	106 0.2×	205 0.6×	41 0.3×	13 0.2×	31	574
Matthias Rastetter Germany	8	153 0.2×	37 0.1×	496 1.5×	90 0.6×	13 0.2×	8	635
Yurong Zhang China	11	199 0.3×	57 0.1×	413 1.2×	91 0.6×	8 0.1×	32	656
Latika Kohli United States	8	50 0.1×	227 0.5×	278 0.8×	25 0.2×	10 0.1×	9	476
Megan L. Goodall United States	7	79 0.1×	457 1.1×	415 1.2×	32 0.2×	6 0.1×	7	696
Juan Esquivel United States	6	71 0.1×	220 0.5×	285 0.8×	52 0.4×	5 0.1×	7	457

Countries citing papers authored by Mark E. Morrison

Since Specialization

Citations

This map shows the geographic impact of Mark E. Morrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Morrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Morrison more than expected).

Fields of papers citing papers by Mark E. Morrison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Morrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Morrison. The network helps show where Mark E. Morrison may publish in the future.

Co-authorship network of co-authors of Mark E. Morrison

This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. Morrison. A scholar is included among the top collaborators of Mark E. Morrison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. Morrison. Mark E. Morrison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Hanna, Nasser H., Paul A. Bunn, Corey J. Langer, et al.. (2006). Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer. Journal of Clinical Oncology. 24(13). 2038–2043. 500 indexed citations breakdown →

2.

Lilenbaum, Rogério, Mark A. Socinski, Nasser K. Altorki, et al.. (2006). Randomized Phase II Trial of Docetaxel/Irinotecan and Gemcitabine/Irinotecan With or Without Celecoxib in the Second-Line Treatment of Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 24(30). 4825–4832. 53 indexed citations

3.

Mathew, Susan, Mark E. Morrison, V.V.V.S. Murty, Alan N. Houghton, & R. S. K. Chaganti. (1994). Assignment of the DPP4 Gene Encoding Adenosine Deaminase Binding Protein (CD26/Dipeptidylpeptidase IV) to 2q23. Genomics. 22(1). 211–212. 7 indexed citations

4.

Morrison, Mark E., Vijayasaradhi Setaluri, Dov Engelstein, Anthony P. Albino, & Alan N. Houghton. (1993). A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase.. The Journal of Experimental Medicine. 177(4). 1135–1143. 143 indexed citations

5.

Morrison, Mark E., et al.. (1985). In vitro studies of 2,4-dihydroxyphenylalanine, a prodrug targeted against malignant melanoma cells.. Proceedings of the National Academy of Sciences. 82(9). 2960–2964. 33 indexed citations

6.

Morrison, Mark E. & Gerald Cohen. (1983). Novel substrates for tyrosinase serve as precursors of 6-hydroxydopamine and 6-hydroxydopa. Biochemistry. 22(24). 5465–5467. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact